Nonparametric estimator of strictly monotone regression function for longitudinal data

来源 :上海交通大学 | 被引量 : 0次 | 上传用户:show_me_the_money
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Recently,longitudinal data have been widely recorded over sparse or dense time points in various imaging studies.
其他文献
Recent advances of wearable computing technology have allowed continuous health monitoring in large observational studies and clinical trials.
Count responses with structural zeros are very common in medical and psychosocial research,especially in alcohol and HIV research,and the zero-inflated Poisson(ZIP)and zero-inflated negative binomial
Most existing binary classification methods target on the optimization of the overall classification risk and may fail to serve some real-world applications such as cancer diagnosis,where users are mo
会议
We study the asymptotic results of linear discriminant analysis(LDA)in large dimensional data where the observation dimension p,is of the same order of magnitude as the sample size n.
The major goals of metagenomics are to identify and study the entire collection of microbial species in a set of targeted samples through sequencing bulk DNA extracted directly from the samples.
The parametric methods,such as autoregressive models or latent growth modeling are usually inflexible to model the dependence and nonlinear effects among the changes of latent traits whenever the time
We develop a novel method called SParse Optimal Transformations(SPOT)to simultaneously select important variables and explore relationships between the response and predictor variables in high dimensi
This paper develops three Bayesian case influence measures including the -divergence,Cooks posterior mode distance and Cooks posterior mean distance to identify influential observations,and a Bayesia
We propose a semiparametric inference approach for the proportional mean residual life model with right-censored length-biased data,which arise frequently in observational studies,espe-cially in epide
Missing data cause challenging issues,particularly in Phase Ⅲ registration trials,as highlighted by the European Medicines Agency(EMA)and the US National Research Council(NRC)..We explore,as a case st